On September 1, 2020 Tavanta Therapeutics, a specialty pharmaceutical company with global headquarters in the Philadelphia, Pennsylvania area, reported its reorganization from Druggability Technologies Holdings Ltd (Hungary) (Press release, Tavanta Therapeutics, SEP 1, 2020, View Source [SID1234564264]). Focused on long-term growth, Tavanta has established a leadership team with a long and successful track record in the development and commercialization of novel specialty drugs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Completing the reorganization of key operational areas of the Company and optimizing our portfolio for strong, sustained growth in the United States have been critical steps for Tavanta," said Chief Executive Officer of Tavanta Therapeutics, Lynne Powell. "We have established a diverse, high-performing leadership team. Each member has enormous breadth and depth of experience and together we look forward to bringing new therapeutic solutions to patients and building value for our stakeholders."
Tavanta Therapeutics has embraced a vibrant, values-based culture that centers on creativity and experience. The name "Tavanta" is a reference to the Company’s commitment to advancing therapeutics designed to improve the lives of patients who have unmet medical needs.
Tavanta uses strategic partnerships early in the drug candidate identification process through in-licensing of drug targets to complement its own internally developed pipeline. The Company also seeks collaborative relationships for the development and commercialization of certain clinical candidates and welcomes inquiries from interested parties.
About the Tavanta Therapeutics Technology Platforms
Tavanta Therapeutics takes a risk-balanced approach to discovery and product development, deploying in-house platforms both to enhance the clinical performance of established molecules and to synthesize novel small molecules and therapeutic peptides. The result is a business model designed to lower the risk associated with the early stages of drug development, aimed toward accelerating new drug candidates into the clinic to reach patients with unmet medical needs.
Tavanta has established two platforms to support the rapid screening, identification and design of drug products for clinical development: High Throughput (HT) Matrix Screening Platform, and the Peptide Conjugate Development (PCD) Platform. The proprietary HT Matrix Screening platform is a bottom-up approach to improving the pharmacokinetic properties of poorly soluble pharmaceuticals, leading to the enhancement of certain important product characteristics. The PCD Platform is an integration of in-vitro and pre-clinical in-vivo testing designed to screen, characterize and design new peptides and peptide conjugates.
At the point at which candidate therapeutics are identified, Tavanta uses established pathways to support focused clinical development and regulatory approval. In the United States, these include both the standard 505(b)(1) and the expedited 505(b)(2) new drug application.